Systematic Reviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2015; 6(4): 64-72
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.64
Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer
Raji Shameem, Muhammad Saad Hamid, Kevin Y Xu, Shenhong Wu
Raji Shameem, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States
Muhammad Saad Hamid, Department of Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, MI 48201, United States
Kevin Y Xu, Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States
Shenhong Wu, Division of Hematology/Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, NY 11794, United States
Shenhong Wu, Northport VA Medical Center, Northport, NY 11768, United States
Author contributions: Wu S designed research; Shameem R and Wu S performed research; Wu S contributed new reagents or analytic tools; Shameem R and Wu S analyzed data; Shameem R, Hamid MS and Xu KY wrote the paper.
Conflict-of-interest statement: Dr. Wu is a speaker for Pfizer and Novartis. No financial support was provided for this study. All remaining authors have declared no conflicts of interests.
Data sharing statement: Technical appendix and statistical code available from the corresponding author atshenhong.wu@stonybrook.edu.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Shenhong Wu, MD, PhD, Associate Professor, Division of Hematology/Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, NY 11794, United States. shenhong.wu@stonybrook.edu
Telephone: +1-631-6381000 Fax: +1-631-6380915
Received: October 26, 2014
Peer-review started: October 28, 2014
First decision: December 26, 2014
Revised: May 18, 2015
Accepted: June 4, 2015
Article in press: June 8, 2015
Published online: August 10, 2015
Core Tip

Core tip: Our meta-analysis has demonstrated that pre-chemotherapy may affect the efficacy and toxicity of abiraterone treatment in patients with metastatic castration-resistant prostate cancer. Abiraterone was associated with significantly increased radiographic-progression-free survival, objective response rate, and prostate-specific antigen response rate in the pre-chemotherapy setting when compared to the post-chemotherapy setting. In addition, abiraterone in the pre-chemotherapy setting had a significant lower risk of all-grade fluid retention and edema (P < 0.001), and hypokalemia (P < 0.001), but had a higher risk of all-grade hypertension (P < 0.001) when compared to post-chemotherapy.